A research team affiliated with UNIST has made a significant discovery explaining why liver cancers associated with obesity and metabolic disorders tend to be more aggressive and less responsive to conventional treatments. The study reveals that a specific signaling pathway involving endotrophin—a protein secreted during liver fibrosis—and the receptor protein CD44 promotes tumor malignancy and drug resistance.
This article was originally published on MedicalXpress.com

